Lack of association between the Cytochrome P450 4F2 rs2108622 genotype and responses to valsartan and amlodipine among a sample of Jordanian hypertensive patients.

BACKGROUND

The Cytochrome 4F2 (CYP4F2) rs2108622 genetic variant influences the production of 20-Hydroxyeicosatetraenoic acid (20-HETE), which affects the blood pressure. Previous findings from our group indicate that CYP4F2 rs2108622 genotype is associated with essential hypertension.

AIMS: This study aims to find out the association of CYP4F2 rs2108622 genotype with the response of valsartan and amlodipine among hypertensive patients.

METHODS

56 hypertensive patients on 80 mg valsartan and 34 on 5 mg amlodipine were genotyped for CYP4F2 rs2108622 genetic variant using PCR-RFLP method. The systolic (SBP) and diastolic (DBP) blood pressures data before and after one month antihypertensive treatment were collected from the computer record of the hospital. The patients were unrelated Arabs attending the University of Jordan Hospital.

RESULTS

We found that carriers of CYP4F2 rs2108622 CC genotype have greater reduction in SBP (mean difference -28.5 ± 15.2 for valsartan and vs. -32.3 ± 5.5 mmHg for amlodipine) in comparison with CT and TT genotypes, this difference did not reach the statistical significance (P value> 0.05). Furthermore, the CYP4F2 rs2108622 genotype was not associated significantly (P value> 0.05) with valsartan and amlodipine responses after adjustment the responses with sex, BMI, age, and smoking status of the patients.

DISCUSSION: While there is a trend suggesting CYP4F2 rs2108622 CC genotype may respond better to valsartan and amlodipine responses, the absence of statistical significance supports the need for larger pharmacogenetic studies.

CONCLUSIONS

It can be concluded from the findings of this study that there is a lack of association between the CYP4F2 rs2108622 genotype and valsartan and amlodipine responses among a sample of Jordanians with essential hypertension.